Document Detail

Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back.
MedLine Citation:
PMID:  23390054     Owner:  NLM     Status:  MEDLINE    
The use of platinated agents in combination chemotherapy regimens for advanced pancreatic cancer is controversial owing to the lack of an outstanding impact on the outcome and a substantial increase in hematologic and extra-hematologic toxicities. Pharmacogenetic studies to identify patients who could benefit most from such therapies are urgently needed. The Xeroderma-Pigmentosum group-D polymorphism at codon-751 (XPD-Lys751Gln) emerged as the most significant independent predictor for death- and progression-risk in our previous study on functional polymorphisms in 122 advanced pancreatic cancer patients treated with cisplatin-docetaxel-capecitabine-gemcitabine and cisplatin-epirubicin-capecitabine-gemcitabine (or EC-GemCap). To confirm the prognostic role of this variable, we further evaluated the correlation of XPD-Lys751Gln with outcome in another 125 patients treated with the same regimens, and 90 treated with gemcitabine monotherapy. Genotyping was successfully carried out in the vast majority of DNA samples. Genotype frequencies followed Hardy-Weinberg equilibrium, and XPD-Lys751Gln was associated with differential progression-free and overall-survival. Multivariate analysis confirmed its prognostic significance in platinum-based regimens. In particular, XPD-Gln751Gln was significantly associated with risk of death (hazard ratio, HR = 1.7, 95% confidence interval [CI], 1.1-2.6, p = 0.011) and risk of progression (HR = 1.7, 95% CI, 1.1-2.5, p = 0.013). No correlation was observed in gemcitabine monotherapy-treated patients. The analysis of DNA damage using extra-long-PCR in lymphocytes supported the association of XPD-Gln751Gln with greater resistance to cisplatin-induced damage. The increasing evidence of XPD-Lys751Gln impact on the outcome of gemcitabine-cisplatin-based polychemotherapy leads to plan prospective studies to validate the role of this polymorphism as a new tool for optimization of the currently available treatments in pancreatic cancer.
Amir Avan; Paola Pacetti; Michele Reni; Michele Milella; Enrico Vasile; Andrea Mambrini; Vanja Vaccaro; Sara Caponi; Stefano Cereda; Godefridus J Peters; Maurizio Cantore; Elisa Giovannetti
Related Documents :
23212764 - Evaluation of the risk of lymph node metastasis using crp 1846c>t genetic polymorphism ...
23117224 - Riluzole and prognostic factors in amyotrophic lateral sclerosis long-term and short-te...
23886164 - Predictive impact of common variations in dna repair genes on clinical outcome of osteo...
24484714 - Completion of radiotherapy is associated with the vulnerable elders survey-13 score in ...
8336184 - Intensively timed induction therapy followed by autologous or allogeneic bone marrow tr...
16035094 - Treatment of wilms tumor according to siop 9 protocol in casablanca, morocco.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2013-03-04
Journal Detail:
Title:  International journal of cancer. Journal international du cancer     Volume:  133     ISSN:  1097-0215     ISO Abbreviation:  Int. J. Cancer     Publication Date:  2013 Aug 
Date Detail:
Created Date:  2013-06-11     Completed Date:  2013-08-12     Revised Date:  2013-09-29    
Medline Journal Info:
Nlm Unique ID:  0042124     Medline TA:  Int J Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1016-22     Citation Subset:  IM    
Copyright Information:
Copyright © 2013 UICC.
Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cisplatin / administration & dosage
Deoxycytidine / administration & dosage,  analogs & derivatives
Glycine / genetics*
Lysine / genetics*
Middle Aged
Pancreatic Neoplasms / drug therapy*,  genetics
Polymerase Chain Reaction
Polymorphism, Genetic*
Xeroderma Pigmentosum Group D Protein / chemistry,  genetics*
Reg. No./Substance:
15663-27-1/Cisplatin; 56-40-6/Glycine; 56-87-1/Lysine; 951-77-9/Deoxycytidine; B76N6SBZ8R/gemcitabine; EC 3.6.1.-/Xeroderma Pigmentosum Group D Protein; EC 5.99.-/ERCC2 protein, human

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  COMMON mechanisms of dysfunctional adipose tissue and obesity- related cancer.
Next Document:  Seat belt injuries of the abdominal aorta in adults--case report and literature review.